3 unknown, 2 active not recruiting, 2 recruiting, 1 not yet recruiting. 8 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Unknown 3, Active not recruiting 2, Recruiting 2, Not yet recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Radical Surgery: new trials by email Literature Review of Radical Surgery trials Research Report on Radical Surgery
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma Sintilimab, Nab-Paclitaxel, Carboplatin - Oral Squamous Cell Carcinoma (OSCC), Head and Neck Squamous Cell Carcinoma | Phase 3 | Not yet recruiting | caohaotian | 300 | 2026-10-01 | 2026-09-18 |
| Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC Camrelizumab, Cisplatin, Nab paclitaxel - Cervical Cancer, Locally Advanced Cervical Cancer | Phase 2 / Phase 3 | Recruiting | Tongji Hospital | 440 | 2024-04-22 | 2024-10-30 |
| A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer Sintilimab, IBI310&Sintilimab, Radical surgery - MSI-H | Phase 3 | Active not recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 453 | 2023-05-25 | 2026-05-28 |
| Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma Camrelizumab, Apatinib Mesylate, Radical surgery - Hepatocellular Carcinoma, Immunotherapy | Phase 3 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 130 | 2023-01-31 | 2024-12-31 |
| Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma Camrelizumab, Apatinib Mesylate, Radical surgery - Hepatocellular Carcinoma, Immunotherapy | Phase 2 / Phase 3 | Active not recruiting | Shanghai Zhongshan Hospital | 294 | 2021-03-25 | 2025-05-11 |
| Neoadjuvant Chemotherapy + Surgery Versus Surgery in FIGO IB2 and IIA2 Cervical Cancer NACT (Paclitaxel + Cisplatin or carboplatin), radical surgery - PFS, OS | Phase 3 | Unknown | Sun Yat-sen University | 700 | 2015-12-01 | 2018-03-16 |
| Neoadjuvant Chemotherapy and Radical Surgery in Stage IIB Cervical Cancer Concurrent chemoirradiation, Paclitaxel, Radical Surgery - Cervical Carcinoma Stage IIB | Phase 3 | Unknown | Sun Yat-sen University | 220 | 2015-11-01 | 2017-02-03 |
| Cytokine-induced Killer Cell Immunotherapy for Surgical Resected Stage III Colorectal Cancer Patients After Chemotherapy Radical surgery, Adjuvant chemotherapy, Cytokine-induced killer cell immunotherapy - Stage III Colon Cancer | Phase 3 | Unknown | Sun Yat-sen University | 550 | 2014-10-01 | 2014-11-05 |
Uterine Cervical Neoplasms (3) · Carcinoma, Hepatocellular (2) · Colonic Neoplasms (1) · Mouth Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Sun Yat-sen University (3) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Shanghai Zhongshan Hospital (1) · The First Affiliated Hospital with Nanjing Medical University (1) · Tongji Hospital (1) · caohaotian (1)
China (8)
Ding Ma (1) · Jian Zhou, Doctor (1) · Jihong Liu, Ph. D (1) · Jihong Liu, Ph.D (1) · Xiao-Jun Wu, Prof. (1) · Xuehao Wang, professor (1) · Yongxiang Xia (1)